Gilead nabs Lilly exec to navigate Kite

12 July 2019

US biotech major Gilead Sciences (Nasdaq: GILD) has lured high pharma profile Christi Shaw to the company as chief executive of CAR-T cancer therapy specialist Kite, which Gilead acquired in an $11.9 billion deal in 2017, and said she will become a member of Gilead’s senior leadership team.

Ms Shaw is a renowned leader with deep experience providing commercial, financial, strategic, medical and operations leadership across the biopharmaceutical industry. Ms Shaw currently serves as senior vice president of Eli Lilly (NYSE: LLY) and president of Lilly Bio-Medicines. She also serves as a board member of both Avantor and the Biotechnology Industry Organization (BIO), and as an advisor to the Healthcare Businesswomen’s Association.

Prior to joining Lilly, Ms Shaw most recently served as US country head and president of Novartis Corp and North American head of Novartis Oncology. She earned a BA in Business Administration from Iowa State University and an MBA from the University of Wisconsin.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK